Global Cell Expansion Supporting Equipment Market Growth 2026-2032
Description
The global Cell Expansion Supporting Equipment market size is predicted to grow from US$ 2133 million in 2025 to US$ 4779 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.
Cell Expansion Supporting Equipment refers to specialized equipment systems used to provide a controlled in vitro or ex vivo environment for adherent culture, suspension culture, perfusion culture, and scale-up of cells. Its core function is to maintain cell viability, proliferation rate, phenotype consistency, and batch-to-batch reproducibility during process scale-up. In physical form, such equipment typically consists of a main control unit, a culture chamber or bioreactor, drive and mixing modules, temperature-control modules, gas supply and exchange modules, fluid paths with pumps and valves, online sensors, and data acquisition/software systems; in closed platforms, sterile connection, sampling, feeding, perfusion, and waste-management components are often integrated as well. By mainstream configuration, it includes rocking systems, stirred bioreactor systems, fixed-bed systems, hollow-fiber systems, gas-exchange culture systems, and integrated automated closed expansion platforms. Its operating principle is to create a suitable microenvironment for different cell types through controlled heat and mass transfer together with feedback control of temperature, pH, dissolved oxygen, carbon dioxide, shear stress, nutrient supply, and metabolite removal, thereby enabling cell expansion from research scale to pilot scale and further to GMP manufacturing scale.
Growth opportunities for Cell Expansion Supporting Equipment are primarily driven by the commercialization of cell and gene therapies, higher process standardization requirements, and the ongoing migration from open manual operations to closed automated manufacturing. As the number of approved cell therapies increases and development pipelines continue to expand, both clinical-stage and commercial-stage manufacturing demand better consistency, lower contamination risk, more complete electronic records, and stronger batch comparability. This is steadily increasing the value of automated expansion platforms, single-use bioreactors, online monitoring tools, and perfusion-control equipment. From the manufacturing perspective, equipment is no longer merely a culture vessel; it has become critical infrastructure directly linked to process development, regulatory compliance, GMP scale-up, and cost control. Suppliers capable of offering closed, modular, digitalized, and verifiable process packages therefore have a stronger chance of being designed into projects.
The main risks of the market are concentrated in process uncertainty, commercialization success rates, validation costs, and supply-chain lock-in. Different cell types, donor sources, and culture routes respond very differently to shear, oxygen transfer, adherent carriers, perfusion strategies, and harvesting methods, which means scale-up is not a simple linear extension of bench-scale parameters. For users, equipment purchase is only one part of total investment; the real barriers lie in process development, validation, consumable systems, software compliance, facility fit, and post-approval change control. For suppliers, a platform that is too closed or too dependent on proprietary consumables may also face customer resistance on cost and flexibility. In addition, although the CGT field remains highly attractive, not every indication will scale commercially at the same pace, and equipment demand will continue to be shaped by financing conditions, clinical outcomes, reimbursement, and capacity utilization.
Downstream demand is moving from “being able to expand cells” toward “being able to scale reliably, manufacture compliantly, and replicate processes across multiple sites.” The strongest current demand comes from cell therapy and advanced therapy manufacturing, upstream biopharmaceutical process development, CDMO/IDMO platforms, and large hospitals or research institutes with translational capabilities. In terms of demand structure, closed systems, automated sampling and feeding, digital batch records, compact parallel development platforms, single-use fluid paths, and low-labor solutions are receiving more attention. From a technical-route perspective, suspension-cell systems remain more favorable for large-scale manufacturing, while adherent-cell systems continue to drive upgrades in fixed-bed, microcarrier, and dedicated carrier-based reactors. Regionally, North America and Europe remain the main centers for high-end platforms and commercial demand, while China, Japan, Singapore, and Israel are increasingly active in localized production, engineering-based cost reduction, and new platform adoption.
LP Information, Inc. (LPI) ' newest research report, the “Cell Expansion Supporting Equipment Industry Forecast” looks at past sales and reviews total world Cell Expansion Supporting Equipment sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Expansion Supporting Equipment sales for 2026 through 2032. With Cell Expansion Supporting Equipment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Expansion Supporting Equipment industry.
This Insight Report provides a comprehensive analysis of the global Cell Expansion Supporting Equipment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cell Expansion Supporting Equipment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Expansion Supporting Equipment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Expansion Supporting Equipment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Expansion Supporting Equipment.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Expansion Supporting Equipment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Flow cytometer
Cell counters
Centrifuges
Others
Segmentation by Process Architecture:
Rocking-motion bioreactor systems
Stirred-tank bioreactor systems
Fixed-bed bioreactor systems
Hollow-fiber bioreactor systems
Orbital-shaken bioreactor systems
Gas-permeable static culture systems
Others
Segmentation by Product Contact Format:
Vessel-based systems
Bag-based systems
Cartridge-based systems
Cassette-based systems
Fiber-module-based systems
Plate or stack-based systems
Others
Segmentation by Single-Use Level:
Reusable stainless-steel systems
Hybrid systems
Single-use systems
Segmentation by Application:
Regenerative Medicine and Stem Cell Research
Cancer and Cell-based Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Danaher (Cytiva)
Thermo Fisher Scientific
Merck
Sartorius
Lonza
Corning
Terumo Blood and Cell Technologies
Miltenyi Biotec
Getinge
Eppendorf
Donaldson (Solaris Biotech)
GEA
ABEC
PHC
Esco Lifesciences Group
Univercells Technologies
Ori Biotech
Cellares
PBS Biotech
Wilson Wolf
Adva Biotechnology
ABLE Biott
Kuhner
Distek
ZETA
INFORS HT
Tofflon
T&J Bioengineering (Shanghai)
Shanghai Zhichu Instrument
Applitech Biological Technology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cell Expansion Supporting Equipment market?
What factors are driving Cell Expansion Supporting Equipment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cell Expansion Supporting Equipment market opportunities vary by end market size?
How does Cell Expansion Supporting Equipment break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Cell Expansion Supporting Equipment refers to specialized equipment systems used to provide a controlled in vitro or ex vivo environment for adherent culture, suspension culture, perfusion culture, and scale-up of cells. Its core function is to maintain cell viability, proliferation rate, phenotype consistency, and batch-to-batch reproducibility during process scale-up. In physical form, such equipment typically consists of a main control unit, a culture chamber or bioreactor, drive and mixing modules, temperature-control modules, gas supply and exchange modules, fluid paths with pumps and valves, online sensors, and data acquisition/software systems; in closed platforms, sterile connection, sampling, feeding, perfusion, and waste-management components are often integrated as well. By mainstream configuration, it includes rocking systems, stirred bioreactor systems, fixed-bed systems, hollow-fiber systems, gas-exchange culture systems, and integrated automated closed expansion platforms. Its operating principle is to create a suitable microenvironment for different cell types through controlled heat and mass transfer together with feedback control of temperature, pH, dissolved oxygen, carbon dioxide, shear stress, nutrient supply, and metabolite removal, thereby enabling cell expansion from research scale to pilot scale and further to GMP manufacturing scale.
Growth opportunities for Cell Expansion Supporting Equipment are primarily driven by the commercialization of cell and gene therapies, higher process standardization requirements, and the ongoing migration from open manual operations to closed automated manufacturing. As the number of approved cell therapies increases and development pipelines continue to expand, both clinical-stage and commercial-stage manufacturing demand better consistency, lower contamination risk, more complete electronic records, and stronger batch comparability. This is steadily increasing the value of automated expansion platforms, single-use bioreactors, online monitoring tools, and perfusion-control equipment. From the manufacturing perspective, equipment is no longer merely a culture vessel; it has become critical infrastructure directly linked to process development, regulatory compliance, GMP scale-up, and cost control. Suppliers capable of offering closed, modular, digitalized, and verifiable process packages therefore have a stronger chance of being designed into projects.
The main risks of the market are concentrated in process uncertainty, commercialization success rates, validation costs, and supply-chain lock-in. Different cell types, donor sources, and culture routes respond very differently to shear, oxygen transfer, adherent carriers, perfusion strategies, and harvesting methods, which means scale-up is not a simple linear extension of bench-scale parameters. For users, equipment purchase is only one part of total investment; the real barriers lie in process development, validation, consumable systems, software compliance, facility fit, and post-approval change control. For suppliers, a platform that is too closed or too dependent on proprietary consumables may also face customer resistance on cost and flexibility. In addition, although the CGT field remains highly attractive, not every indication will scale commercially at the same pace, and equipment demand will continue to be shaped by financing conditions, clinical outcomes, reimbursement, and capacity utilization.
Downstream demand is moving from “being able to expand cells” toward “being able to scale reliably, manufacture compliantly, and replicate processes across multiple sites.” The strongest current demand comes from cell therapy and advanced therapy manufacturing, upstream biopharmaceutical process development, CDMO/IDMO platforms, and large hospitals or research institutes with translational capabilities. In terms of demand structure, closed systems, automated sampling and feeding, digital batch records, compact parallel development platforms, single-use fluid paths, and low-labor solutions are receiving more attention. From a technical-route perspective, suspension-cell systems remain more favorable for large-scale manufacturing, while adherent-cell systems continue to drive upgrades in fixed-bed, microcarrier, and dedicated carrier-based reactors. Regionally, North America and Europe remain the main centers for high-end platforms and commercial demand, while China, Japan, Singapore, and Israel are increasingly active in localized production, engineering-based cost reduction, and new platform adoption.
LP Information, Inc. (LPI) ' newest research report, the “Cell Expansion Supporting Equipment Industry Forecast” looks at past sales and reviews total world Cell Expansion Supporting Equipment sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Expansion Supporting Equipment sales for 2026 through 2032. With Cell Expansion Supporting Equipment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Expansion Supporting Equipment industry.
This Insight Report provides a comprehensive analysis of the global Cell Expansion Supporting Equipment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cell Expansion Supporting Equipment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Expansion Supporting Equipment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Expansion Supporting Equipment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Expansion Supporting Equipment.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Expansion Supporting Equipment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Flow cytometer
Cell counters
Centrifuges
Others
Segmentation by Process Architecture:
Rocking-motion bioreactor systems
Stirred-tank bioreactor systems
Fixed-bed bioreactor systems
Hollow-fiber bioreactor systems
Orbital-shaken bioreactor systems
Gas-permeable static culture systems
Others
Segmentation by Product Contact Format:
Vessel-based systems
Bag-based systems
Cartridge-based systems
Cassette-based systems
Fiber-module-based systems
Plate or stack-based systems
Others
Segmentation by Single-Use Level:
Reusable stainless-steel systems
Hybrid systems
Single-use systems
Segmentation by Application:
Regenerative Medicine and Stem Cell Research
Cancer and Cell-based Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Danaher (Cytiva)
Thermo Fisher Scientific
Merck
Sartorius
Lonza
Corning
Terumo Blood and Cell Technologies
Miltenyi Biotec
Getinge
Eppendorf
Donaldson (Solaris Biotech)
GEA
ABEC
PHC
Esco Lifesciences Group
Univercells Technologies
Ori Biotech
Cellares
PBS Biotech
Wilson Wolf
Adva Biotechnology
ABLE Biott
Kuhner
Distek
ZETA
INFORS HT
Tofflon
T&J Bioengineering (Shanghai)
Shanghai Zhichu Instrument
Applitech Biological Technology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cell Expansion Supporting Equipment market?
What factors are driving Cell Expansion Supporting Equipment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cell Expansion Supporting Equipment market opportunities vary by end market size?
How does Cell Expansion Supporting Equipment break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
178 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Cell Expansion Supporting Equipment by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Cell Expansion Supporting Equipment by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
